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ABSTRACT
Background: In Th2 immune responses, TSLP is a key player by induction of OX40-ligand (OX40L) on den-
dritic cells (DCs), which is the trigger to induce Th2 cell-mediated allergic cascade. Thus, TSLP-DC-OX40L
axis might be the principal pathway in the inflammatory cascades in atopic dermatitis and asthma. IL-33, which
is produced by epithelial cells, has been implicated in the Th2 immune responses and pathogenesis of the al-
lergic disorders. However, the role of IL-33 in the Th2-polarizing TSLP-DC-OX40L axis still remains largely elu-
sive. We focused on the ability of IL-33 to promote OX40L-mediated Th2 responses.
Methods: Purified human naïve or memory CD4+ T cells were stimulated with recombinant OX40L or TSLP-
treated DCs (TSLP-DCs) in the presence of IL-33, and the cytokine production by the primed T cells was exam-
ined. We also performed immunohistochemical analyses for the expression of IL-33 in specimens of lymph
node and skin from the patients with atopic dermatitis.
Results: IL-33 remarkably enhanced TSLP-DCs-driven or OX40L-driven Th2 responses from naïve T cells
and the Th2 functional attributes of CRTH2+ CD4+ Th2 memory cells by the increased production of IL-5, IL-9,
and IL-13. In addition, IL-33 was expressed in the nuclei of epithelial cells in not only skin lesion but also lymph
nodes of the patient with atopic dermatitis, suggesting a specialized role in adaptive T cell-priming phase.
Conclusions: IL-33 works as a positive regulator of TSLP-DC-OX40L axis that initiates and maintains the Th2
cell-mediated inflammatory responses, and therefore, it would be a new therapeutic target for the treatment of
allergic disorders.
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INTRODUCTION
The prevalence of allergic diseases, such as atopic
dermatitis, asthma, and allergic rhinitis, has in-
creased.1 These allergic disorders are characterized
by inflammatory processes in which the T helper type
2 (Th2) cells are crucial for the initiation and mainte-
nance of allergic immune responses.2 Th2 cell-
derived cytokines such as IL-4, IL-5, and IL-13, induce
the activation of immunological effector system as-
sembled by B cells, eosinophils, and mast cells, lead-
ing to increased IgE concentrations, mast-cell de-
granulation, mucus hypersecretion, and eosinophil-
mediated inflammation.3 Recently, it has been clari-
fied an integral role of dendritic cells (DCs) in the cel-
lular cascade that initiate Th2 responses in allergy.4
Furthermore, thymic stromal lymphopoietin (TSLP),5
an epithelial cell-derived cytokine, is found to equip
DCs with a programming role in Th2 polarization in
allergic inflammation.6 TSLP is highly expressed by
keratinocytes in the skin of patients with atopic der-
matitis6 and by airway epithelial lesion of patients
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with asthma.7 Also in mice, overexpression of TSLP
develops atopic dermatitis-like skin lesion with infil-
tration of Th2 cells and elevated serum IgE, and trig-
gers bronchial allergic inflammation.8 TSLP receptor-
deficient mice failed to induce antigen-specific inflam-
matory Th2 cell response and asthma in response to
inhaled antigen.9 Thus, TSLP appears to be the first
epithelial cell-derived cytokine that directly triggers
DC-mediated Th2 allergic inflammation, which is the
critical cascade downstream in allergic disease patho-
genesis.10 The human CD11c+ myeloid DCs activated
by TSLP prime naïve Th cells to differentiate into in-
flammatory Th2 cells that produce IL-4, Il-5, IL-13 and
high levels of TNF-α while little IL-10 and interferon-
γ.6 In this process, OX40 ligand (OX40L), which is
preferentially induced on human DCs by TSLP, has
been identified as a principal mediator that induces
the generation of inflammatory Th2 cells.11 Thus, the
interacting axis of OX40L on DCs and OX40 on T
cells is the essential element in inducing aberrant in-
flammatory Th2 cells that cause allergic disorders.
In addition, memory Th2 cells are the principal
cells responsible for the maintenance of chronic aller-
gic inflammation and the relapse of allergic inflamma-
tion upon re-exposure to allergens.12,13 TSLP-
activated DCs (TSLP-DCs) also play a role of homeo-
static expansion of allergen-specific Th2 memory
cells and further polarization of the Th2 phenotypes
through OX40L expression,14 contributing to the
maintenance of chronic allergic inflammation. With
regard to this point, another epithelial cell-derived cy-
tokine IL-25 plays an enhancing role of function and
expansion of Th2 memory cells induced by TSLP-
DCs.15 Thus, the OX40L on DCs and epithelial cell-
derived cytokines might be the early and principal
molecular components that trigger and maintain the
allergic inflammatory cascades in diseases such as
atopic dermatitis and asthma.16,17
IL-33, identified as an epithelial cell-derived cy-
tokine in the IL-1 family, is found to be synthesized as
a 30-kDa precursor molecule and cleaved by caspase-
1 upon inflammasome activation into an 18-kDa ma-
turebioactive form.18 IL-33 is mainly expressed in a
variety of non-hematopoietic cells such as fibroblasts,
adipocytes, smooth muscle, endothelial, and bron-
chial epithelial cells.18-20 The formerly orphaned IL-1
receptor-related protein, ST2, is found to be the IL-33
receptor,21 and IL-33ST2 axis activates immune cells
involved in allergic inflammation such as Th2
cells,18,22 NKT cells,23 eosinophils,24 basophils,25 mast
cells,26 and group 2 innate lymphoid cells.27 Indeed,
increased IL-33 expression is found in inflamed skin
tissue of atopic dermatitis patients28 and in the serum
of asthmatic patients,29 and IL-33 has been implicated
in the pathogenesis of asthma, atopic dermatitis, and
anaphylactic shock.30 IL-33 functions as selective Th2
chemoattractant and enhances the IL-5 and IL-13 ex-
pression in mouse Th2-polarized cells in vitro, lead-
ing to severe pathological changes in mucosal organs
with epithelial hyperplasia and eosinophil and neutro-
phil infiltrations in the colonic mucosa.18 Further-
more, IL-33 is found to activate mouse bone marrow-
derived myeloid DCs to prime naïve T cells to pro-
duce IL-5 and IL-1331,32 and to directly stimulate
mouse naïve CD4+ cells to differentiate into Th2 cells
producing IL-5 and IL-13,33 indicating a contribution
to Th2-oriented allergic inflammation. Of interest is
that IL-33 has been described as a chromatin-
associated transcriptional regulating factor.34 Thus,
IL-33 has dual roles; an intracellular nuclear factor
and a Th2-inducing cytokine. Given the functional in-
volvement of IL-33 in the Th2 immune responses and
allergic inflammation, we hypothesized that human
IL-33 plays a possible role in the key Th2-polarizing
cascade, the generation and maintenance of OX40L-
dependent pathway. Here we have investigated how
IL-33 participates in OX40L-mediated Th2 immune re-
sponses, and how it mediates the progress in allergic
inflammatory cascades. In this study, we have shown
that IL-33 is a positive regulator of TSLP-DC-OX40L
axis that potentiates the differentiation from human
naïve Th cells to Th2 cells and expansion of memory
Th2 cells, and it dramatically enhances the produc-
tion of allergy-associated cytokines, IL-5, IL-9 and IL-
13.
METHODS
MEDIA AND REAGENTS
RPMI-1640 supplemented with 2 mM L-glutamine,
100 Uml penicillin, 100 ngml streptomycin and
heat-inactivated 10% fetal bovine serum (Invitrogen,
Carlsbad, CA, USA) was used for cell cultures
throughout the experiments. We used 15 ngml
TSLP (R&D Systems, Minneapolis, MN, USA), 1 μg
ml R848 (InvivoGen, San Diego, CA, USA), recombi-
nant IL-4 (R&D Systems) and 10 μgml recomibinant
IL-33 (R&D Systems). Recombinant OX40LCD32-
transfected L fibroblasts as OX40L stimulation and
CD32-transfected L fibroblasts as control were used
for T cell stimulation, as described previously.35
ISOLATION AND CULTURE OF BLOOD DCs
Human peripheral blood DC subsets (myeloid DCs
and pDCs) were isolated from PBMCs from healthy
adult donors, as described previously.36 The CD11c+
DCs were cultured in flat-bottom 96-well plates in the
presence of TSLP, R848, or IL-33 at 5 × 104 cells in
200 μl of medium per well for 24 h.
PURIFICATION OF NAÏVE AND CRTH2+CD4+
MEMORY T CELL SUBSET
CD4+ T cells were enriched using CD4+ T cell isola-
tion kit II (Miltenyi Biotec, Teterow, Germany) ac-
cording to the manufacturer’s instructions. Enriched
CD4+ T cells were stained with FITC-labeled lineage
cocktail (CD8, CD14, CD16, CD19, CD56, BDCA2,
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TCR-αβ, and glycophorin A) or PE-Cy5.5-labeled
anti-CD4, allophycocyanin-labeled anti CD45RA (BD
Biosciences, Franklin Lakes, New Jersey, USA), or
biotin-labeled anti-CRTH2 (Miltenyi Biotec) followed
by allophycocyanin-labeled anti-streptavidin (BD Bio-
sciences). Stained cells were sorted by fractions of
CD4+CD45RA+ naïve T cells and CD4+CRTH2+ Th2
memory cells (purity >99%).
ANALYSES OF DCs
To analyze the expression of surface molecules, DCs
were stained with FITC-labeled CD86 mAb (BD Bio-
sciences) and PE-labeled anti-OX40L mAb (Ancell,
Bayport, MN, USA), and then analyzed by a
FACSCalibur (BD Biosciences). Isotype matched
mAbs (R&D Systems) were used as negative con-
trols.
T CELL STIMULATION
2 × 104 freshly purified naïve CD4+ T cells (DC-to-
T cell ratio, 1 : 4) were cocultured with allogeneic
CD11c+ DCs precultured with different conditions for
24 h, and 1 × 104 freshly purified CRTH2+CD4+ Th2
memory cells (DC-to-T cell ratio, 1 : 2) were cocul-
tured with autologous CD11c+ DCs in 96-well round-
bottom culture plates for 7 days. In some experi-
ments, T cells were cultured for 5 days with irradi-
ated OX40LCD32-transfected L fibroblasts (2.5 ×
104well) as a platform to immobilize the stimulating
anti-CD3 (OKT3, 0.2 μgml) and anti-CD28 (0.2 μg
ml) mAbs. CD32-transfected L fibroblasts were used
as control L fibroblasts (parental L fibroblasts).
SURFACE MARKER ANALYSES OF T CELLS
Th cells were stained with PE-labeled ST2 (anti-IL-33
receptor) mAb (Medical & Biological Laboratories,
Nagoya, Japan) or anti-CD124 (IL-4 receptor α) mAb
to determine their expressions. Isotype matched PE-
labeled unrelated mAbs (R&D Systems and Beckman
Coulter, Brea, CA, USA) were used as negative con-
trols.
ANALYSES OF T CELL CYTOKINE PRODUC-
TION
The cultured CD4+ T cells were collected and
washed. For detection of cytokine production in the
culture supernatants, the T cells were restimulated
with immobilized anti-CD3 (OKT3, 5 μgml) and sol-
uble anti-CD28 (1 μgml) at a concentration of 106
cellsml for 24 h. The levels of IL-4, IL-5, IL-10, IL-9,
IL-13, TNF-α, and IFN-γ were measured by ELISA
(kits from R&D Systems or eBioscience, San Diego,
CA, USA).
T CELL EXPANSION ASSAY
Freshly isolated 2 × 104 CRTH2+CD4+ Th2 memory
cells were stimulated for 5 days with CD32-
transfected or CD32OX40L-transfected L fibroblasts
precoated with anti-CD3 (OKT3, 0.2 μgml) and anti-
CD28 (0.2 μgml) mAbs, as described above. The
cultured T cells were collected and resuspended in an
EDTA-containing medium to dissociate the clusters.
Viable cells were counted by trypan blue exclusion of
the dead cells.
COLLECTION OF HUMAN SAMPLES
This study was approved by the Institutional Review
Board of Kansai Medical University (PBMCs from
healthy adult donors; IRB No. 0640 and specimens
from patients with atopic dermatitis; IRB No. 0793)
and the research was in compliance with the Helsinki
declaration. This study was approved by the review
board for human research at Kansai Medical Univer-
sity. Skin specimens were taken by 6-mm punch biop-
sies from normal skin of healthy subject and lesional
skin of atopic dermatitis defined according to stan-
dard clinical criteria. IRB No. 0640 includes blood col-
lection and IRB No. 0793 includes skin biopsy from
our collaborators (as healthy volunteers) for this re-
search. In these collections, informed consent acqui-
sition was performed by our collaborators with free
intention. When developed lymph node swelling was
observed, lymph node specimens from the patients
with atopic dermatitis were also taken by biopsies.
IMMUNOHISTOCHEMISTRY
Immunohistochemical staining was performed on fro-
zen sections of human skin specimen. After fixation
in acetone, specimens were stained with monoclonal
anti-IL-33 mAb (R&D Systems) or isotype control,
and the avidin-biotin-peroxidase complex method us-
ing a labelled streptavidin-biotin kit (Dako, Glostrup,
Denmark) before visualization of the immunoreac-
tions. After immunodetection, the sections were
counterstained with hematoxylin.
RESULTS
IL-33 DID NOT ACTIVATE HUMAN MYELOID DCs
TO INDUCE THE EXPRESSION OF OX40L
It has been reported that IL-33, like TSLP, is pro-
duced from the epithelial tissue, particularly from the
skin in lesion with atopic dermatitis,37 and activate
mouse bone marrow-derived myeloid DCs to express
OX40L and CCL17.31 Therefore, we first examined
whether IL-33 can activate human CD11c+ myeloid
DCs to induce the up-regulation of OX40L and CD86
on cell surface. In line with the previous studies,6,11
TSLP showed the strong ability to induce DC activa-
tion by the substantial upregulation of OX40L, CD86,
but TLR ligand R848 only induced CD86 upregulation
(Fig. 1). We here found that IL-33 could barely in-
duce the increase in the expression of OX40L and
CD86 on human blood myeloid DCs (Fig. 1). Addi-
tion of IL-33 together with TSLP did not induce fur-
ther upregulation of these molecule expression com-
pared with TSLP alone. This result indicates a less
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Fig.　1　Surface marker analyses on DCs after the culture with IL-33. Human 
blood myeloid CD11c+ DCs were isolated from the peripheral blood, and 
were cultured with medium alone, TSLP, R848, or IL-33 (50 ng/ml) for 24 hrs. 
The DCs were then stained with mAb against CD86 or OX40L (fi lled histo-
grams), and analyzed by a FACSCalibur. The DCs stained with isotype-
matched controls were represented as open histograms. Similar results were 
observed in four independent experiments and the results of a representative 
experiment are shown.
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ability of IL-33 to activate human myeloid DCs, unlike
mouse DCs, at least with respect to the expression of
OX40L and CD86. Thus, unlike TSLP, which directly
activates human DC subset to mediate Th2 response,
IL-33 could not induce the strong DC activation in hu-
mans in vitro.
IL-33 ENHANCES TSLP-DC-MEDIATED Th2 CELL
RESPONSE IN OX40L AXIS
We next assessed the direct effect of IL-33 on the
CD4+ T cells for Th2-polarizing axis. IL-33 itself had
an ability to induce Th2 cells that produce IL-5, IL-9,
and IL-13 (Fig. 2A) and had no effects of IL-4, IL-10,
TNFα, nor IFNγ production, when naïve T cells were
stimulated with anti-CD3 and CD28 mAbs, this being
dose-dependent fashion of IL-33 (Fig.2B). As has
been reported, Th2 polarization was synergistically
enhanced by IL-4 and OX40L.11 Thus, we next exam-
ined whether IL-33 and DC-derived OX40L could
work synergistically in driving Th2 cell responses.
Naïve CD4+ T cells were cocultured for 7 days with al-
logeneic DCs pretreated with TSLP (TSLP-DCs), and
the cytokine production by the primed CD4+ T cells
was then examined. Addition of IL-33 into the cocul-
ture of TSLP-DCs and naïve T cells induced a marked
increase in the productions of IL-5, IL-9, and IL-13, as
shown in Figure 3. This was the case when naïve T
cells were stimulated with OX40L-transfected L fibro-
blasts with anti-CD3CD28 mAbs (instead of TSLP-
DCs). Increased productions of IL-4, IL-5, IL-9, IL-13,
IL-33 Enhances OX40L-Driven Th2 Response
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Fig.　2　Effect of IL-33 on naïve Th cell differentiation. Freshly purifi ed naïve CD4+ T cells were stimulated with immo-
bilized anti-CD3/CD28 mAbs on CD32 transfected-L fi broblasts in the presence or absence of IL-33 (A; 50 ng/ml and B; 
different doses). Five days after the initiation of the culture, the supernatants were collected and the amounts of cyto-
kines indicated in the fi gures were determined by ELISA. Data are means ± s.e.m. of fi ve independent experiments. 
Statistical signifi cance was determined using paired Student’s t test (*, p < 0.05).
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and TNFα with decreased productions of IL-10 and
IFNγ were observed when T cells were stimulated
with OX40L-transfected L cells (Fig. 4A), whereas the
Th2 polarization was further promoted by the addi-
tion of IL-33, as indicated in the dramatically elevated
production of IL-5, IL-9, and IL-13 without affection of
IL-4, IL-10, TNFα, nor IFNγ (Fig. 4A). Therefore, IL-
33 can collaboratively promote the Th2 differentiation
with OX40L.
To identify the mechanism underlying this proc-
ess, we analyzed surface expression of IL-33 (ST2) on
T cells stimulated with OX40L-transfected L fibro-
blasts. Freshly isolated naïve T cells and activated T
cells cultured with anti-CD3CD28 mAbs expressed
little IL-33R (Fig. 4B). Interestingly, recombinant
OX40L upregulated their surface expression of IL-
33R (Fig. 4B), indicating that DC-derived OX40L cre-
ates a susceptible condition of developing Th2 cells to
IL-33.
IL-33 ENHANCES IL-4-MEDIATED Th2 CELL RE-
SPONSE
IL-4 is another critical environmental Th2 polarizing
signal.38-40 Next, we examined synergistic function of
IL-33 and IL-4 in the Th2 polarization. Naïve T cells
were stimulated with IL-4 and anti-CD3CD28 mAbs
for 7 days. Unlike OX40L, IL-4 contributes to the gen-
eration of conventional Th2 cells that produce IL-5,
IL-9, IL-13, and IL-10 but not TNF-α production (Fig.
5A). When IL-33 was added to the culture, the pro-
ductions of IL-5, IL-9, and IL-13 were remarkably ele-
vated without affection of IL-10, IFN-γ, nor TNF-α
(Fig. 5A), as tested in the culture with TSLP-DCs
(Fig. 3) and with OX40L-transfected L fibroblasts
(Fig. 4A). Thus, IL-33 also enhances the Th2 re-
sponse elicited by IL-4.
Next, we cultured naïve T cells with IL-33 to deter-
mine whether IL-33 can enhance the expression of IL-
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Fig.　3　Effect of IL-33 on TSLP-DC-mediated Th2 cell responses. The blood myeloid CD11c+ DCs were cultured with 15 
ng/ml of TSLP (TSLP-DCs). Freshly isolated naïve CD4+ T cells were cocultured with allogeneic TSLP-DCs (DC-to-T cell 
ratio, 1 : 4) in the presence of graded doses of IL-33 (10-200 ng/ml) for 7 days. Cytokine production by CD4+ T cells was 
measured in supernatants by ELISA. Data are means ± s.e.m. of fi ve independent experiments. Statistical signifi cance was 
determined using paired Student’s t test (*, p < 0.05).
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4R (CD124) and whether IL-4 can enhance the IL-33R
(ST2) on T cells. Although activated T cells cultured
with anti-CD3CD28 mAbs expressed detectable sur-
face IL-4R, IL-33 further increased their expression of
IL-4R (Fig. 5B). Meanwhile, stimulation of T cells
with IL-4 in the presence of anti-CD3CD28 mAbs en-
hanced the expression of IL-33R (Fig. 4B). Addition
of IL-33 into IL-4 showed less effect on their expres-
sion. Thus, the mutual positive effect between IL-33
and IL-4 on the T cell expression of IL-4R and IL-33R
might enhance the Th2 transition.
IL-33 ENHANCES MEMORY Th2 CELL RE-
SPONSE
CRTH2+ memory T cells continuously stimulated by
allergens play a critical role for the maintenance of
the allergic condition and OX40L on TSLP-DCs in-
duces expansion of CRTH2+ memory T cells.14,41
Therefore, we next examined the effect of IL-33 on
the activation of CRTH2+ memory Th2 cells. Isolated
CRTH2+ memory T cells were stimulated with anti-
CD3CD28 mAbs on the OX40L-transfected L fibro-
blasts or the parental control L cells in the presence
or absence of IL-33. We here found that OX40L stimu-
lation enhanced the expansion of CRTH2+ memory T
cells and this effect was further amplified when added
with IL-33 (Fig. 6A). Next, we analyzed surface ex-
pression of IL-33R on CRTH2+ memory T cells.
Freshly isolated CRTH2+ memory T cells expressed
detectable IL-33R and their expression was slightly
upregulated after culture with anti-CD3CD28 mAbs
(Fig. 6B). OX40L stimulation further increased their
expression of IL-33R (Fig. 6B), leading to a suscepti-
ble condition to IL-33. In either case stimulated with
autologous TSLP-DCs or with OX40L-transfected L fi-
broblasts plus anti-CD3CD28 mAbs, the increased
productions of IL-5 and IL-13 from CRTH2+ CD4+ Th2
memory cells were observed when IL-33 was added
in the culture (Fig. 6C). Thus, IL-33 can activate
CRTH2+ memory T cells to further produce Th2 cy-
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Fig.　4　Effect of IL-33 on OX40L-mediated Th2 cell responses. A: Naïve Th cells were cultured on OX40L-transfected L fi bro-
blasts with immobilized anti-CD3/CD28 mAbs in the presence or absence of IL-33 (50 ng/ml). Naïve Th cells cultured with 
CD32-transfected L fi broblasts (parental L cells) plus anti-CD3/CD28 mAbs were served as controls. Five days after the initia-
tion of the culture, the supernatants were collected and the amounts of cytokines indicated in the fi gures were determined by 
ELISA. Data are means ± s.e.m. of fi ve independent experiments. Statistical signifi cance was determined using paired Stu-
dent’s t test (*, p < 0.05; **, p < 0.01). B: Naïve Th cells were stimulated with OX40L-transfected L fi broblasts or parental L cells 
with immobilized anti-CD3/CD28 mAbs in the presence or absence of IL-33 and/or IL-4 for 5 days. Before and after culture, the 
cells were stained with mAb against ST2 (IL-33R). The staining profi les of ST2 and isotype-matched control are indicated by 
shaded and open areas, respectively. Similar results were observed in three independent experiments and the results of a rep-
resentative experiment are shown.
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Fig.　5　Effect of IL-33 on IL-4-mediated Th2 cell responses. A: Naïve Th cells were stimulated with immobi-
lized anti-CD3/CD28 mAbs (CD32-transfected L fi broblasts (parental L cells) were used as a platform) and IL-4 
(25 ng/ml) in the presence or absence of IL-33 (50 ng/ml). Five days after the initiation of the culture, the super-
natants were collected and the amounts of cytokines indicated in the fi gures were determined by ELISA. Data 
are means ± s.e.m. of fi ve independent experiments. Statistical signifi cance was determined using paired Stu-
dent’s t test (*, p < 0.05; **, p < 0.01). B: Naïve Th cells were stimulated on CD32-transfected L fi broblasts with 
immobilized anti-CD3/CD28 mAbs in the presence or absence of IL-33 (50 ng/ml) for fi ve days. The cells were 
stained with mAb against IL-4R (CD124). The staining profi les of IL-4R and isotype-matched control are indicat-
ed by shaded and open areas, respectively. Similar results were observed in three independent experiments 
and the results of a representative experiment are shown.
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Fig.　6　Effect of IL-33 on memory Th2 cell responses. Memory Th2 cells, isolated as CD4+CRTH2+cells, were stimulated with 
autologous TSLP-DCs (DC-to-T cell ratio, 1 : 2) for 7 days or with OX40L-transfected L fi broblasts plus immobilized anti-CD3/
CD28 mAbs for 5 days in the presence or absence of IL-33 (50 ng/ml). A: After culture with OX40L-transfected L fi broblasts 
(OX40L) or parental L cells (Cont.), viable T cells were counted with a trypan-blue exclusion test. Horizontal bars indicate the 
median of four independent experiments. Statistical signifi cance was determined using paired Student’s t test (*, p < 0.05). B: 
Before and after culture with OX40L-transfected L fi broblasts (OX40L) or parental L cells (Cont.), the cells were stained with 
mAb against ST2 (IL-33R). The staining profi les of ST2 and isotype-matched control are indicated by shaded and open areas, 
respectively. Similar results were observed in three independent experiments and the results of a representative experiment 
are shown. C: After culture with TSLP-DCs, OX40L-transfected L fi broblasts or parental control L cells, the supernatants were 
collected and the amounts of cytokines indicated in the fi gures (vertical axis) were determined by ELISA. Data are means ± 
s.e.m. of fi ve independent experiments. Statistical signifi cance was determined using paired Student’s t test (*, p < 0.05; **, p 
< 0.01).
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Fig.　7　Expression of IL-33 in the lesional skin and lymph node in the patients with atopic dermatitis. Immunohistochemical
staining was performed on frozen sections of human specimen. A-C: Staining with anti-IL-33 mAb of biopsied skin specimen
from the patients with atopic dermatitis. B shows keratinocytes (left open square in A) and C shows endothelial cells (right open
square in A) of lesional skin. Representative data from two patients are shown. D: Staining with anti-IL-33 mAb of biopsied skin
specimen from the normal volunteers. Representative data from two donors are shown. E and F: Staining with anti-IL-33 mAb of
biopsied lymph nodes from the patients with atopic dermatitis. F shows crypt epithelial cells in the lymph nodes (open square in
E). Representative data from two patients are shown. Original magnifi cation × 20 in A, D, and E; × 50 in B, C and F. Arrows in F
indicate crypt epithelial cells that are positive for IL-33. Scale bar, 10 μm.
A B C
D
E F
tokines and it also assists their survival to maintain
the allergic state.
IL-33 EXPRESSION IN SKIN AND INFLAMED
LYMPHOID TISSUE OF ATOPIC DERMATITIS
The relevance of IL-33 expression in allergic diseases
was confirmed by several immunohistochemical stud-
ies in the inflamed skin tissue of atopic dermatitis,28,37
in the serum of asthmatic patients,29 and in the lungs
of mice with experimental allergic asthma.42 Because
of the present data showing the direct effects of IL-33
on Th2 polarization, we hypothesized that IL-33 could
be expressed in lymphoid tissues where DCs prime
naïve and memory T cells. Therefore, we performed
immunohistochemical analyses to examine the ex-
pression of IL-33 in inflamed lymphoid tissues as well
as skin specimen from the patients with atopic derma-
titis.
Immunohistochemical staining revealed that most
of nuclei in hypertrophic keratinocyte layer were
more or less positive for IL-33 in the patients with
atopic dermatitis (Fig. 7A, B). In atopic dermatitis pa-
tients but not the normal volunteer (Fig. 7D), IL-33
expression was upregulated in the entire skin. In ad-
dition, strong nuclear expression of IL-33 in endothe-
lial cells of lesional skin from the patients with atopic
dermatitis (Fig. 7C). More importantly, the strong
nuclear expression of IL-33 was also detected at the
crypt epithelial cells in the lymph nodes from the pa-
tients with atopic dermatitis (Fig. 7E, F). This finding
implies a potential role of IL-33 in T cell priming in al-
lergic inflammation. Thus, epithelial cell-derived IL-
33 can positively regulate the OX40L-driven Th2-
polarizing axis, leading to reinforcement of allergic
responses in the regional area.
DISCUSSION
IL-33 is involved in the allergy-associated responses
in which the activity of neutrophils and monocytes
macrophages have been influenced to increase cy-
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tokine productions.43 Furthermore, it is noted that IL-
33 can directly act on both eosinophils to enhance
their survival, adhesion, and CD11b expression be-
cause of their abundant expression of ST244 and baso-
phils to induce the enhanced secretion of pro-
inflammatory cytokines including IL-4, IL-5, IL-13,
and CD11b expression along with their migratory ac-
tivity.23,25 It has recently been reported that IL-33 can
support the expansion of newly identified innate im-
mune effector nuocytes that mediate Th2 immune re-
sponse by producing IL-4, IL-5 and IL-1345 and that
IL-33 expressed on skin may play an important role in
pathogenesis of atopic dermatitis through activation
of the innate lymphoid cells.46 Together with these
roles in the innate immunity, IL-33 also plays some
roles in acquired type 2 immune responses through
activating DCs and promoting Th2 cell differentia-
tion.31-33 Given these findings that IL-33 has various
effects on different cell types, IL-33 could be a key cy-
tokine that enhances and coordinates both innate and
acquired allergic immune responses.
In addition to these functions of IL-33, we here
found that IL-33 can participate in the Th2-polarizing
DC-mediated OX40L effect as an important pathway
to induce allergic response. IL-33 enhances IL-5 and
IL-13 production in the developing Th2 cells medi-
ated by OX40L not only in Th2 differentiation from
naïve T cells but also on maintenance of memory Th2
cells. Unlike in the case of mouse DCs, which can re-
spond to IL-33 to undergo maturation with their
upregulated expression of OX40L,31 direct respon-
siveness of human myeloid DCs to IL-33 was quite
weak. This difference in the responsiveness of IL-33
to DCs between humans and mice still remains un-
clear and further studies will be required to deter-
mine how human DCs become to strongly respond to
IL-33. Although OX40L cause allergic inflammation
by concomitant promotion of inflammatory cytokine
TNF-α production with development of Th2 cells,11,35
our results suggest that IL-33 might contribute to the
Th2 immune response by promoting the functional
attributes of producing IL-5 and IL-13 on the OX40L-
driven Th2 cell differentiation and maintenance with-
out affecting TNF-α.
IL-5 has been reported to support the terminal dif-
ferentiation and proliferation of eosinophilic precur-
sors and to recruit eosinophils to the inflammatory
site,47 and thus, the recruited eosinophils produce cy-
totoxic substances such as major basic protein,
eosinophilic cationic protein, and eosinophilic peroxi-
dase, leading to tissue damage. In addition to this, IL-
13, another upregulated cytokine by IL-33, could play
a critical role in the development of bronchial asthma
by airway hypersensitivity48 and contribute to asth-
matic airway obstruction by increase in the mucin se-
cretion in the epithelial cells and mucus metapla-
sia,49,50 which has been confirmed by the findings
that IL-13 affects both ciliated and secretory cell dif-
ferentiation in animal models of asthma51 and that it
also induces mucin secretion through TGF-β2 up-
regulation.52 Thus, in the context of Th2 cytokine-
associated allergic response, IL-33 can be indirectly
involved in the enhancement of inflammatory re-
sponses and aggravation of pathogenic condition
through the increases in IL-5 and IL-13 production.
Of note is that in our results, IL-33 enhanced the
production of IL-9 in the developing Th2 cells in-
duced by either TSLP-DCs or OX40L. Th9 cells are
closely associated with Th2 cells, as Th2 cells co-
express both IL-4 and IL-9 in the early phase of Th2
differentiation, and the Th2 cytokine IL-4 provides
one of the key signals for Th9 induction.53 In addi-
tion, OX40L leads to a remarkable increase in Th9 dif-
ferentiation from naïve CD4+ T cells.54 Recently, it
has been reported that IL-33 induces IL-9 production
in Th2 cells and basophils,55 and IL-9 has been previ-
ously implicated in the pathogenesis of asthma and
other allergic diseases in human studies.56-58 Thus,
IL-33 is also involved in the Th2-mediated allergic in-
flammation in line with the production of IL-9, which
possesses various effects on different cell types in
which it promotes mast cell growth and production of
proinflammatry cytokines IL-1β and IL-6 and also IL-5
and IL-13.59 Furthermore, IL-9 is suggested to be a
key molecule that affects differentiation of Th17 cells
along with TGF-β1 through activation of STAT3.60
Therefore, upregulation of IL-9 production induced
by IL-33 leads to an increase in inflammatory cells
and worsening of regional allergic state.
Based on our finding showing the expression of IL-
33 in the crypt epithelial cells in the lymph nodes, to-
gether with the fact that IL-33 is constitutively ex-
pressed in high endothelial venules and fibroblastic
reticular cells in normal lymphoid tissues,19 it has
been speculated that IL-33 expression in the epithe-
lial and endothelial cells in lymphoid tissues can par-
ticipate in the allergic adaptive responses by enhanc-
ing the DC-driven Th2 differentiation from naïve T
cells through OX40L at the T cell priming phase. By
contrast, considering the function of IL-33 as
chemoattractant for Th2 cells and the distribution of
infiltrated CRTH2+ memory Th2 cells co-localized
with DCs in the dermis of lesional skin of atopic der-
matitis,14 skin-derived IL-33 expression might be re-
lated to the aggravation of chronic atopic dermatitis
by its ability to maintain memory Th2 cells after the
recruitment to the skin lesional area.
Our study now identifies the nature of the re-
sponses elicited by IL-33, which might pathophysi-
ologically amplifies both OX40L-driven inflammatory
Th2 immune responses and IL-4-mediated classical
Th2 cell differentiation. Although IL-4 is the critical
Th2-polarizing factor,39 human DCs activated by
TSLP or other stimuli have no capacity to produce IL-
4.6,11 Therefore, IL-4 is not the DC-derived original
trigger of Th2 responses. Recent studies have sug-
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gested that basophils are most likely the key source
of IL-4 in induction of Th2 immunity.61 Thus,
basophil-IL-4 axis, in addition to DC-OX40L axis,
might be another pathway in driving Th2-type im-
mune response. With respect to this context, IL-33 is
found to target basophils to induce activation and pro-
duction of IL-4.62 Therefore, our results suggest that
IL-33 links DC-OX40L axis and basophil-IL-4 axis to
tailor the Th2 type immune responses.
In conclusion, we identified a specialized role of IL-
33, which works as a positive regulator of DC-OX40L
axis that promotes the differentiation from naïve Th
cells into Th2 cells and maintain memory Th2 cells.
Based on our and other findings,30,63 IL-33 would be
recognized as an important epithelial cytokine system
to contribute to the Th2 immune responses besides
IL-25 and TSLP. Therefore, the regulation of IL-33
production is one of the therapeutic plans that amelio-
rate allergic states. Thus, our results provide a new
insight into the biological action of IL-33 underlying
the Th2-mediated allergic response and would pave
the way for the development of therapeutic strategy
to ameliorate allergic diseases such as atopic dermati-
tis or asthma.
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